

AMENDMENTS

IN THE CLAIMS:

Please cancel claim 5 without prejudice or disclaimer, and amend the remaining claims as follows:

---

1. (Twice Amended) An adenosine-5'-diphosphate (ADP)-ribosylation inhibitor comprising proanthocyanidin which has been purified to a tetramer or higher fraction as an effective ingredient, wherein proanthocyanidin is the one purified using a substance selected from the group consisting of a styrene adsorption resin, an anionic exchange resin, an octadecyl-chemically binding silica gel, an octyl-chemically binding silica gel, a phenyl-chemically binding silica gel and a silica gel.

2. (Not Amended) An ADP-ribosylation inhibitor according to claim 1, wherein proanthocyanidin is obtained from an edible plant or an edible plant-derived material.

3. (Not Amended) An ADP-ribosylation inhibitor according to claim 2, wherein said edible plant or edible plant-derived material is an extract from an apple or a grape.

4. (Previously Twice Amended) An ADP-ribosylation inhibitor according to claim 1, wherein proanthocyanidin is the one extracted with at least one solvent selected from the group consisting of water, an alcohol, and ester and a ketone.

5. (Canceled).

6. (Three Times Amended) A composition for the treatment and/or prevention of diphtheria, pertussis, tetanus and opportunistic infection, comprising as an effective ingredient an ADP-ribosylation inhibitor comprising proanthocyanidin which has been purified to a tetramer or higher fraction as an effective ingredient, wherein proanthocyanidin is the one purified using a substance selected from the group consisting of a styrene adsorption resin, an anionic exchange resin, an octadecyl-chemically binding silica gel, an octyl-chemically binding silica gel, a phenyl-chemically binding silica gel and a silica gel.

7. (Amended) A composition for the treatment and/or prevention of enterotoxin type bacterial infectious disease comprising proanthocyanidin as an effective ingredient, wherein proanthocyanidin is the one purified using a substance selected from the group consisting of a styrene adsorption resin, an anionic exchange resin, an octadecyl-chemically binding silica gel, an octyl-chemically binding silica gel, a phenyl-chemically binding silica gel and a silica gel.

8. (Not Amended) A composition for the treatment and/or prevention of enterotoxin type bacterial infectious disease according to claim 7, which is for the treatment and/or prevention of cholera, botulinus and traveler's diarrhea.

9. (Previously Amended) A composition for the treatment and/or prevention of enterotoxin type bacterial infectious disease according to claim 7, wherein said edible plant or said edible plant-derived material is an extract from an apple or a grape.

10. (Previously Twice Amended) A composition for the treatment and/or prevention of enterotoxin type bacterial infectious disease according to claim 7, wherein proanthocyanidin is the

one extracted with at least one solvent selected from the group consisting of water, an alcohol, an ester and a ketone.

11. (Previously Twice Amended) A composition for the treatment and/or prevention of enterotoxin type bacterial infectious disease according to claim 7, wherein proanthocyanidin is the one purified using a substance selected from the group consisting of a styrene adsorption resin, an anionic exchange resin, an octadecyl-chemically binding silica gel, an octyl-chemically binding silica gel, a phenyl-chemically binding silica gel and a silica gel.

12. (Not Amended) A composition for the treatment and/or prevention of enterotoxin type bacterial infectious disease according to claim 2, wherein proanthocyanidin is obtained from an edible plant or an edible plant-derived material.

13. (Not Amended) A composition for the treatment and/or prevention of enterotoxin type bacterial infectious disease according to claim 12, wherein said edible plant or edible plant-derived material is an extract from an apple or a grape.

14. (Not Amended) A composition for the treatment and/or prevention of enterotoxin type bacterial infectious disease according to claim 6, wherein the proanthocyanidin has been purified to a pentamer or higher fraction as an effective ingredient.

15. (Not Amended) A composition for the treatment and/or prevention of enterotoxin type bacterial infectious disease according to claim 6, wherein the proanthocyanidin has been purified to hexamer and higher fractions as an effective ingredient.

16. (Not Amended) An adenosine-5'-diphosphate (ADP)-ribosylation inhibitor according to claim 1 comprising proanthocyanidin which has been purified to a pentamer or higher fraction as an effective ingredient.

17. (Not Amended) An adenosine-5'-diphosphate (ADP)-ribosylation inhibitor according to claim 1 comprising proanthocyanidin which has been purified to hexamer and higher fractions as an effective ingredient.

18. (Amended) A method for the treatment ~~and/or prevention~~ of enterotoxin type bacterial infectious disease comprising proanthocyanidin as an effective ingredient, comprising administering to a patient in need of such treatment a composition comprising proanthocyanidin, wherein proanthocyanidin is the one purified using a substance selected from the group consisting of a styrene adsorption resin, an anionic exchange resin, an octadecyl-chemically binding silica gel, an octyl-chemically binding silica gel, a phenyl-chemically binding silica gel and a silica gel.

19. (Not Amended) A method according to claim 18, wherein the bacterial infectious disease is cholera, botulinus or traveler's diarrhea.

20. (Not Amended) A method according to claim 18, wherein proanthocyanidin has been purified to a pentamer or higher fraction.

21. (Not Amended) A method according to claim 18, wherein proanthocyanidin has been purified to hexamer and higher fractions.